论文部分内容阅读
目的探讨低分子肝素钙治疗肺心病急性加重期的疗效及其安全性。方法纳入肺心病急性加重期患者共80例,随机分为2组,观察组和对照组各40例。对照组采用常规治疗,观察组在常规治疗的同时加用低分子肝素钙4000IU,Q12h,腹壁皮下注射,连续应用5～7d,观察两组症状、体征及实验室检查的改变。结果治疗后观察组和对照组总有效率分别为95.0%和72.5%,差异有明显统计学意义(P<0.05);治疗后观察组SaO2、PaO2、PaCO2、肺动脉压和左室射血分数改善明显优于对照组(P<0.05);两组患者在治疗过程中均未见明显不良反应。结论 :低分子肝素钙治疗肺心病急性加重期能明显改善缺氧和微循环状态,改善心肺功能,疗效显著,安全性好,值得推广应用。
Objective To investigate the efficacy and safety of low molecular weight heparin in the treatment of acute pulmonary cor pulmonale. Methods A total of 80 patients with acute exacerbation of pulmonary heart disease were enrolled in this study. They were randomly divided into 2 groups, 40 in each of observation group and control group. The control group was treated with routine treatment. The observation group was treated with low molecular weight heparin 4000IU, Q12h and subcutaneous injection of abdominal wall for 5 ~ 7 days. The symptoms, signs and laboratory changes of the two groups were observed. Results After treatment, the total effective rates of the observation group and the control group were 95.0% and 72.5%, respectively, with significant difference (P <0.05). After treatment, SaO2, PaO2, PaCO2, pulmonary arterial pressure and left ventricular ejection fraction were improved Significantly better than the control group (P <0.05); no significant adverse reactions in both groups in the course of treatment. Conclusion: Low molecular weight heparin treatment of pulmonary heart disease in acute exacerbation period can significantly improve the state of hypoxia and microcirculation, improve cardiopulmonary function, significant effect, good safety, it is worth popularizing and applying.